RxDoctor Payments Data

Enio Prieto, MD

Internal Medicine · Sebastian, FLNPI 1063498384

Payments from drug & device makers

$2,694in general payments, 2019–2025

Across 138 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$362
  • Pfizer$317
  • Lilly USA, LLC$264
  • Astellas Pharma US Inc$247
  • Amgen$227
  • AstraZeneca$149
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,50593%
  • Education$1897%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,694 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$597,644
Medicare patients
847
Services billed
34,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide190$211,157
OzempicSemaglutide138$198,433
EliquisApixaban199$176,794
JardianceEmpagliflozin102$115,319
XareltoRivaroxaban61$58,880
Dupixent SyringeDupilumab11$44,225
EntrestoSacubitril/Valsartan33$39,604
TrulicityDulaglutide31$38,792
VraylarCariprazine Hcl26$35,994
LinzessLinaclotide31$35,274
Repatha SureclickEvolocumab32$30,392
ProliaDenosumab17$28,884
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$25,527
JanuviaSitagliptin Phosphate27$25,016
Tresiba Flextouch U-100Insulin Degludec37$22,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$264$249,950221 claims
Novo NordiskOzempic$362$198,433138 claims
PfizerEliquis, Nurtec Odt$317$194,879217 claims
AbbVieVraylar, Linzess, Synthroid$130$75,396127 claims
Johnson & JohnsonXarelto$63$58,88061 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$149$40,13055 claims
NovartisEntresto$91$39,60433 claims
GSKTrelegy Ellipta, Anoro Ellipta$149$37,13444 claims
AmgenProlia$227$28,88417 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$15$14,80414 claims
Astellas Pharma US IncMyrbetriq$247$10,80917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sebastian

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →